In patients with metastatic CRNEC with deficient mismatch repair (dMMR), high microsatellite instability (MSI-H), and BRAF mutation, addition of immune checkpoint inhibitor therapy is recommended.[16,19,26,29,44,49] Our patient received such therapy but did not undergo a tumor cell molecular study. This evidence concerns the gene BRAF and neoplasm.